|
Orthologous residues
|
|
SMTNL1 (human): S354‑p, SMTNL1 (mouse): S301‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'muscle, smooth'-thoracic aorta
|
|
Cellular systems studied:
tissue
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
norepinephrine
|
|
|
|
increase
|
|
|
isoproterenol
|
|
|
|
increase
|
|
|
ACh
|
|
|
|
increase
|
|
|
cGMP analog
|
|
|
|
increase
|
|
|
cAMP analog
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
inhibition
|
|
Comments:
reduces inhibitory effect of SMTNL1 on myosin phosphatase SMPP1M in vitro
|
